Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 billion in an all-cash deal as per the latest pharma acquisition news. Dermira, which is being acquired for $18.75 per share, has been engaged in developing dermatology products for the […]
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin disorders, from XBiotech, in a deal worth up to $1.35 billion, as per the latest pharma acquisition news. Bermekimab, which is an anti-IL-1alpha monoclonal antibody (mAb), […]
Continue reading …Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis (AD). Etrasimod is a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator. Atopic dermatitis is considered to be a serious, chronic immune-mediated disease in which symptoms are varied. However, the usual […]
Continue reading …Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment of moderate-to-severe atopic dermatitis. The late-stage clinical trial will feature adult patients, who are randomly grouped in a double-blinded, placebo-controlled study that will assess the efficacy and safety of the […]
Continue reading …Teva Pharmaceutical Industries has launched a generic version of Elidel (pimecrolimus) Cream, 1% in the US, a topical prescription medicine indicated for use as a second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis). Elidel (pimecrolimus) Cream, 1% has approval to be used for the treatment of non-immunocompromised […]
Continue reading …LEO Pharma, a Danish pharma company, has bagged global exclusive rights for atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP) in a deal worth around KRW450 billion ($402 million). The global licensing agreement will not cover South Korea, the home country of JWP, where the Korean pharma company will keep its exclusive rights over the […]
Continue reading …Novartis has agreed to acquire the exclusive global development and marketing rights of atopic dermatitis drug MOR106 from MorphoSys and Galapagos in a deal that could go up to $1.1 billion. The Swiss drugmaker will make an upfront payment of €95 million ($111 million) to Galapagos and MorphoSys apart from potential milestone payments of up […]
Continue reading …Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Dupixent eczema injection with that has become the first ever biologic medicine approved for atopic dermatitis treatment in patients whose disease is not managed adequately […]
Continue reading …Atopic dermatitis clinical trial : The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the primary endpoints of a crucial one-year long phase 3 clinical trial in adult patients with uncontrolled moderate-to-severe atopic dermatitis (AD). Update : Dupixent eczema injection gets FDA approval for atopic dermatitis treatment Atopic Dermatitis Clinical Trial […]
Continue reading …